NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer

Olayioye, Monilola A.; Neve, Richard M.; Lane, Heidi A.; Hynes, Nancy E.

doi:10.1093/emboj/19.13.3159

Cited by 2,237 publications

(1,947 citation statements)

References 124 publications

(157 reference statements)

Supporting

Mentioning

1,877

Contrasting

Unclassified

Order By: Relevance

“…Epidermal growth factor receptors are commonly active in a dimeric form and interaction between different EGF receptor pairs represents a mechanism for signal diversification and amplification (Olayioye et al, 2000;Yarden and Sliwkowski, 2001). Various dimeric pairs depend on the concentration of receptors, the concentration of particular ligands and the affinity of the receptors towards each other (Pinkas-Kramarski et al, 1996;Tzahar et al, 1997).…”

mentioning

confidence: 99%

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients

et al. 2006

View full text Add to dashboard Cite

Increased expression of the epidermal growth factor (EGF) receptors, HER1 and HER2 are related to poor prognosis in most cancers studied. Recently, a high expression of the two remaining receptors of the EGF system, HER3 and HER4 has been related to a favourable prognosis. However, prognostic significance of HER1 and HER2 receptors in bladder cancer is controversial and the effect of the expression of different combinations of these receptors on patient survival is not well understood. Therefore, we examined the mRNA expression of all four EGF receptors with real-time polymerase chain reaction in biopsies from 88 patients with bladder cancer, where the survival was followed for a median of 38.5 months (range 1 -117 months). Expression of HER1 and HER2 alone showed no correlation with survival. However, a high expression of HER1 together with high expression of HER3 and HER4 correlated to a better prognosis compared to the high expression of HER1 together with low expression of HER3 and HER4 (P ¼ 0.0006). Also, a significantly longer survival was observed in patients expressing high HER2 when coexpressed with high HER3 and HER4, as compared to the survival in patients with tumours expressing high HER2 but low HER3 and HER4 (P ¼ 0.0005). Our results suggest that the final outcome of patients with high HER1-and HER2-expressing tumours depends on the expression of HER3 and HER4.

show abstract

mentioning

confidence: 99%

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Epidermal growth factor receptor and HER-2 belong to the c-erb receptor family (Downward et al, 1984;Coussens et al, 1985), and are implicated in cell proliferation, differentiation and migration in physiological processes. In cancerogenesis, their overexpression leads to abnormal cell proliferation (Ullrich and Schlessinger, 1990;Klapper et al, 2000;Olayioye et al, 2000). Epidermal growth factor receptor can be overexpressed through diverse and mainly post-transcriptional mechanisms.…”

mentioning

confidence: 99%

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

et al. 2005

View full text Add to dashboard Cite

Squamous cell carcinoma of the oesophagus (SCCO) is still a pathology of bad prognosis. Specific therapies are now developed against epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2, c-kit receptor (CD117), vascular endothelial growth factor (VEGF) and p53 protein. This study was aimed at assessing their expression in a large series of SCCO, as well as their potential therapeutic interest in this pathology. Immunohistochemical expression of these factors was assessed retrospectively in 107 cases of SCCO with primary surgery, as well as their relationships to recurrence, metastasis and overall survival on a long-term follow-up. Human epidermal growth factor receptor 2 and CD117 were expressed in less than 3% of the cases. Epidermal growth factor receptor and p53 were overexpressed in 68.2 and 66.4% of the cases, and VEGF in 38.3%. Epidermal growth factor receptor overexpression was significantly related to vascular invasion (P ¼ 0.023). Its diffuse positivity was significantly related in multivariate analysis to higher local recurrence (P ¼ 0.006) and lower overall survival (P ¼ 0.003), in a subgroup of patients of poor outcome who had received postoperative adjuvant treatment. These results highlight the great potential prognostic and therapeutic interest of evaluating EGFR diffuse positivity in locally advanced SCCO.

show abstract

“…A large number of clinical studies have linked ErbB2 amplification and/or overexpression with poor prognosis in breast cancer (Olayioye et al, 2000). Collaborative work including our laboratory revealed that high ErbB2 signaling activity is associated with poor outcome in breast cancer, and that this activity (and negative prognosis) is itself associated with high expression of the EGFR (Thor et al, 2002;DiGiovanna et al, 2005).…”

Section: Introductionmentioning

confidence: 97%

“…ErbB3 is often overexpressed in mammary carcinoma, which in some cases may occur through collaboration with ErbB2 (Siegel et al, 1999). Cooperation of ErbB2 and ErbB3 is important for aggressiveness of ErbB2-overexpressing cancers (Olayioye et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4

et al. 2006

View full text Add to dashboard Cite

The four members of the ErbB family of receptor tyrosine kinases are involved in development and tumorigenesis of the mammary gland. Whereas the epidermal growth factor receptor, ErbB2 and ErbB3 are positively associated with various cancers, clinical studies of ErbB4 in breast cancer are contradictory. Results from tissue culture analyses and some clinical studies suggested that ErbB4 is either a tumor suppressor or is a negative regulator of ErbB2-driven tumors. Neu-Cre-ErbB4 flox/null mice in which ErbB4 was inactivated by Cre-lox-mediated recombination in the mammary gland developed MMTVNeu-driven mammary tumors with a similar latency period to mice with one or two wild-type ErbB4 alleles. Moreover, there was no difference in the histologies of tumors that developed, nor in the propensity to form lung metastases. Taken together these results suggest that ErbB4 is not a potent, highly penetrant tumor suppressor, nor is it a factor in Neu-mediated tumorigenesis in this model.

show abstract

NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer

Cited by 2,237 publications

References 124 publications

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer

Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4

Contact Info

Product

Resources

About